There is no established SLU-PP-332 injection dosage for humans. Learn what animal studies used, how oral and injectable routes differ, and the safety unknowns.
There is no established SLU-PP-332 injection dosage for humans. SLU-PP-332 is a research chemical that has never entered human clinical trials, so no safe, effective, or even tested injectable dose exists. Every number circulating online — micrograms, milligrams, once daily or twice daily — comes from rodent studies or anecdotal self-reporting, not from clinical guidance.
Why No Validated Human SLU-PP-332 Injection Dosage Exists
SLU-PP-332 is a pan-ERR agonist studied as a potential exercise mimetic. It has been characterized in cell cultures and rodent models, and that is where the evidence stops.
- No human trials. No Phase 1 safety study has been registered or published, which means researchers do not know a tolerable dose, let alone an effective one.
- No human pharmacokinetics. Half-life, clearance, tissue distribution, and bioavailability in people are all unknown.
- No injectable data at all. Even in animals, most published work used oral gavage or intraperitoneal administration, not the subcutaneous injections people ask about.
Without those basics, any specific injectable number is invention rather than science. A dose that suppresses appetite in a mouse tells you almost nothing about what happens in a 180-pound adult human.
What the Animal Research Actually Used
The best-known rodent work on this compound used oral gavage doses in the range of 50 mg/kg per day, with follow-up experiments exploring higher exposures. Doses that large would be impossible to translate directly to humans because of how differently the two species handle the molecule.
| Model / Setting | Route | Reported Dose | Notes |
|---|---|---|---|
| Obese mice (metabolic studies) | Oral gavage | ~50 mg/kg per day | Improved endurance and fat oxidation in animals |
| Follow-up rodent work | Oral gavage | Up to ~100 mg/kg | Dose-dependent effects; no human comparison |
| Exploratory tolerability work | Intraperitoneal | Roughly 10–50 mg/kg | Laboratory route, not a human protocol |
| Humans | Any route | None documented | No clinical trial data exists |
Allometric scaling — the math used to convert animal doses to human equivalents — is a rough estimate even for well-studied drugs. For a compound with unknown human metabolism, it produces a wide and unreliable range rather than a real answer.
SLU-PP-332 Oral vs Injection: How the Routes Differ
People search for slu-pp-332 oral vs injection because the two routes are assumed to behave differently, and in general they do. An injection bypasses first-pass liver metabolism, which often raises bioavailability. With an uncharacterized molecule, that same shortcut could also amplify unknown effects, and there is no published data showing what injected SLU-PP-332 does in any species.
| Factor | Oral | Injection |
|---|---|---|
| Human dosing data | None | None |
| Preclinical precedent | Common in rodent studies | Very limited |
| Human bioavailability | Unknown | Unknown |
| Sterility requirement | Lower | Higher; product is not sterile-grade |
| Regulatory status | Research chemical only | Research chemical only |
Why Forum Numbers Don't Translate Into a Real Dose
Community posts about slu-pp-332 dosage usually cite microgram-to-low-milligram ranges with no source, no lab verification, and no follow-up bloodwork. Vials sold to consumers are often labeled “not for human use,” may vary in actual purity, and are rarely third-party tested.
Search interest in slu-pp-332 oral dosage per day is high, largely because oral use is easier and matches the animal research route. That still does not create a human dose. Content marketed as a “slu-pp-332 dosage for men” is also a framing device rather than biology — with zero human pharmacokinetic data, there is no scientific basis for sex-specific dosing.
Handling, Purity, and Injection Risks
Injectable products carry risks that oral research chemicals do not, and those risks are independent of the dose question.
- Research-grade powder is not manufactured to USP sterile-injectable standards.
- Reconstitution introduces contamination risk when supplies and technique are not pharmaceutical-grade.
- Miscalculated concentrations can cause accidental overdose by orders of magnitude.
- Impurities and synthesis byproducts may be present with no requirement to disclose them.
Anyone weighing how to take slu-pp-332 should treat the sterility and purity questions as seriously as the dose question, because an infection or a contaminated vial can cause harm regardless of how little compound is injected.
SLU-PP-332 Side Effects and the Unknowns
There is no human safety database for this compound, so reported slu-pp-332 side effects are self-reported and unverified. ERRs are active in skeletal muscle, heart, liver, kidney, and breast tissue, which means an unstudied agonist could plausibly affect organs well beyond fat and muscle.
The slu-pp-332 benefits described in the literature — increased running endurance, resistance to diet-induced weight gain, and better insulin sensitivity — come from mice, not people. Mouse results frequently fail to replicate in humans. Long-term effects, interactions with prescription medications, and cardiac risk are all uncharacterized, and anyone considering it should speak with a physician instead of relying on vendor claims or forum logs.
The Bottom Line
- No human SLU-PP-332 injection dosage has been established, and no clinical trial has ever tested one.
- Rodent studies used roughly 50 mg/kg per day by oral gavage, a figure that cannot be safely converted to a human injection.
- Injectable SLU-PP-332 has no preclinical precedent, so both the effects and the risks are unknown.
- SLU-PP-332 is not FDA-approved for human use and is legally sold only as a research chemical.
- Self-reported doses online are unverified and should not be treated as a protocol.
For anyone genuinely interested in exercise mimetics, the responsible path is watching for peer-reviewed human trials and discussing options with a licensed healthcare professional — not experimenting with an unapproved injectable research compound.
Frequently Asked Questions
What is the correct SLU-PP-332 injection dosage?
There is no correct or established SLU-PP-332 injection dosage for humans. The compound has never been tested in a clinical trial, so no safe or effective human dose has been identified. Numbers posted online are extrapolations from mouse studies or anecdotal reports and are not clinically validated.
Can you inject SLU-PP-332 instead of taking it orally?
Injection is not a studied route for SLU-PP-332 in any species, so there is no data on its effects or safety. Injectable use also adds sterility and contamination risks because research-grade powder is not manufactured to injectable standards. Oral gavage was the route used in the published rodent research.
Is SLU-PP-332 safe for human use?
No human safety data exists for SLU-PP-332. Its target receptors are active in muscle, heart, liver, and other tissues, so unstudied effects outside of metabolism are possible. It is sold for research use only and is not FDA-approved as a drug or supplement.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.